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Chapter 1 - Introduction  
 
Neuroplasticity is a feature of the human brain to dynamically reorganize itself structurally as 
well as functionally in response to changes of the environment, behavior or brain injury. It can 
be accomplished via adding, removing, strengthening or weakening of synaptic connections as 
well as neurogenesis (Pascual-Leone et al., 2005, Pascual-Leone et al., 2011). Besides being one 
of the most important physiological mechanisms of learning, memory and other cognitive 
processes, pathologically altered neuroplasticity can cause neuropsychiatric diseases. The 
discovery and development of non-invasive brain stimulation techniques in the last decades has 
given researchers the opportunity to study neuroplasticity in humans. Transcranial magnetic 
stimulation (TMS), transcranial direct current stimulation (tDCS) and paired associative 
stimulation (PAS) are widely used techniques for non-invasively inducing and monitoring these 
processes in the human brain (Nitsche and Paulus, 2000, Stefan et al., 2000, Nitsche et al., 2008, 
Ziemann et al., 2008).  
The present work is divided into two parts: first, the deeper exploration of mechanisms 
influencing brain plasticity using modified brain stimulation protocols and the second part, 
representing the impact of two major neuromodulators (serotonin and nicotine) on non-invasive 
brain stimulation-induced neuroplasticity. Several studies have previously demonstrated the 
impact of different neuromodulators on different types of plasticity in humans (Kuo et al., 2007, 
Kuo et al., 2008, Monte-Silva et al., 2009, Nitsche et al., 2009, Monte-Silva et al., 2010b, 
Thirugnanasambandam et al., 2012). In this thesis we aimed to study the impact of serotonin on 
synapse-specific focal plasticity induced by PAS and the dose-dependent effect of  nicotinic 
receptor activation on plasticity.  
The first chapter of this thesis will introduce basic information about neuroplasticity, 
neuromodulatory systems and techniques used in the studies presented in the second chapter. 
The last chapter will summarize the findings of the presented studies and offer an outlook and 
possible future research directions in the field.  
 
CHAPTER 1 - INTRODUCTION 
 
3 
1.1. Plasticity in the central nervous system 
 
Neuroplasticity is an intrinsic property of the nervous system to modify, optimize and reorganize 
itself structurally or functionally in response to physiological or environmental changes and 
injuries (Citri and Malenka, 2008). Functional plasticity accomplished by long-lasting changes in 
the central nervous system, such as long term potentiation (LTP) and long term depression (LTD), 
is considered to be a mechanism of learning and memory formation. LTP and LTD have been 
most frequently studied for glutamatergic synapses in various brain areas and have been shown 
to be mediated by NMDA receptors that have calcium channel properties (Bliss and Collingridge, 
1993, Malenka and Bear, 2004). Therefore, the major factor determining the direction of 
plasticity at a specific synapse is the postsynaptic calcium concentration (Lisman, 2001). It has 
been shown that low postsynaptic calcium concentration results in LTD, high concentration in 
LTP, and at a medium concentration a so-called “no man’s land” exists at which no plasticity 
results (Cho et al., 2001, Lisman, 2001). Very high Ca2+ concentrations can also result in no 
plasticity due to activation of hyperpolarizing potassium channels (Misonou et al., 2004). Low 
intracellular calcium concentration triggers a cascade of intracellular reactions leading to 
removal of AMPA receptors from the synaptic membrane, weakening synaptic strength and 
resulting in LTD. In contrast, high calcium influx into the neuron results in activation of the 
opposite mechanism, enhancing the insertion of AMPA receptors in the subsynaptic membrane, 
resulting in LTP (Cummings et al., 1996, Malenka and Bear, 2004). 
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Figure 1. Illustration of LTP and LTD induction mechanisms at a glutamatergic synapse. 
Depending on intracellular calcium concentration, a specific cascade of cytoplasmic reactions is 
triggered, leading to either LTP or LTD. Induction of LTP is followed by an addition of AMPA 
receptors to the synaptic membrane via exocytosis, respectively, removal of AMPA receptors 
occurs after LTD induction via endocytosis, thus the strength and efficacy of synaptic 
transmission is altered (adapted from (Citri and Malenka, 2008)). 
 
1.2. Neuroplasticity in humans: the motor cortex as a model 
 
Neuroplasticity in humans has been the subject of intensive studies during the past decades, and 
has been increasingly recognized as an important physiological basis for learning, and memory 
processes. Various studies demonstrate brain plasticity in healthy individuals. For example, in 
mathematicians gray matter density in the left inferior frontal and bilateral inferior parietal 
lobules (regions, related to mathematical thinking) is significantly higher than in controls (Aydin 
et al., 2007). Similarly, magnetic resonance imaging (MRI) studies have revealed increased gray 
matter density in motor, auditory cortex and cerebellum in musicians, compared to controls 
(Gaser and Schlaug, 2003). Another MRI study revealed increased gray matter density in the left 
inferior parietal cortex of bilingual subjects compared to monolinguals (Mechelli et al., 2004). 
Changes in gray matter density in regions associated with learning and memory (posterior and 
lateral parietal cortex and hippocampus) were demonstrated in medical students who were 
preparing for an exam, compared to controls who did not study at that time (Draganski et al., 
2006). Studies have also revealed that blind subjects have larger representation of fingers in the 
somatosensory maps due to increased tactile discrimination abilities (Pascual-Leone and Torres, 
1993) and rearrangements in visual areas due to echolocation (Thaler et al., 2011). 
In the clinical domain, studies suggest that depression might be caused by altered brain 
plasticity, namely, enhanced inhibitory and reduced excitatory plasticity (Christoffel et al., 2011). 
In accordance, results of a recently published study revealed deficits in motor learning and 
PAS25-induced excitatory plasticity in patients with depression compared to healthy controls 
(Player et al., 2013). Imaging studies also show changes in hippocampal volume in patients 
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suffering from depression (Sheline et al., 1996, Sheline et al., 2003, Campbell et al., 2004). In 
stroke patients, excitatory plasticity was also shown to be reduced (Traversa et al., 1997, 
Traversa et al., 1998). Functional MRI studies in stroke patients subjects also revealed changes in 
motor and sensory maps throughout the rehabilitation process, correlating with recovery 
(Liepert et al., 1998, Levy et al., 2001, Hodics et al., 2006, Johansen-Berg et al., 2010).  
In recent years, non-invasive brain stimulation techniques, such as repetitive transcranial 
magnetic stimulation (TMS), transcranial direct current stimulation (tDCS) and paired associative 
stimulation (PAS) allow researchers to induce plasticity in humans (Nitsche and Paulus, 2000, 
Stefan et al., 2000, Huang et al., 2004a). These techniques induce changes of cortical excitability 
and can be monitored by recording TMS-elicited motor evoked potentials (MEPs). The motor 
cortex was used as a model in most of the studies conducted so far, as it is relatively well 
explored, easy reachable using TMS and tDCS, because it is situated at the brain surface 
(especially, small hand muscle representations), and MEPs are relatively objective output 
parameters for measuring cortical excitability. In all our studies, we obtained MEPs from the 
abductor digiti minimi (ADM) or first dorsal interosseus (FDI) muscles elicited by single or paired-
pulse TMS to monitor plasticity.  
 
1.3. Non-invasive brain stimulation techniques  
 
The first method to non-invasively access and stimulate cortical neurons in the human brain was 
transcranial electric stimulation (TES) (Merton and Morton, 1980). To activate cortical neurons 
and induce action potentials, this method uses a high voltage current, which also activates 
cutaneous and meningeal pain receptors as well as head muscles, and therefore is 
uncomfortable and painful for the subjects. In 1985 another non-invasive brain stimulation 
technique – TMS was developed (Barker et al., 1985). Unlike TES, the TMS magnetic pulse 
penetrates the skull, induces a secondary electric field in the brain and neuronal action 
potentials, without activating pain receptors and head muscles. Thus, TMS became very popular 
for monitoring of cortical excitability. Single-pulse TMS-induced MEPs have shown to be 
objective measures of cortical excitability (Rothwell, 1993). Repetitively applied TMS pulses have 
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been shown to induce long-lasting cortical excitability changes depending on the frequency of 
application (Pascual-Leone and Hallett, 1994, Huang et al., 2004a). When combined with 
peripheral nerve stimulation, TMS can also produce excitability changes, depending on the 
interstimulus interval (ISI). This method is called paired associative stimulation (PAS) and induces 
plasticity similar to spike-timing dependent plasticity (STDP), which is thought to be involved in 
learning and memory processes (Stefan et al., 2002, Wolters et al., 2003, Caporale and Dan, 
2008).  
Apart from rTMS, another non-invasive brain stimulation technique was introduced some years 
ago, which induces polarity-dependent changes in cortical excitability using subthreshold direct 
current (tDCS) (Nitsche and Paulus, 2000). 
 
1.3.1. Transcranial magnetic stimulation  
 
TMS pulses induce rapidly changing magnetic fields in cortical structures, which results in 
secondary electric fields and current flow opposite to magnetic coil orientation. If this current is 
sufficiently large, it can depolarize neurons. In the motor cortex, a suprathreshold TMS pulse can 
activate cortical representations of a specific hand or leg muscle, eliciting motor evoked 
potentials (MEP). TMS-elicited MEPs can be recorded using surface electromyography (EMG) 
electrodes (Rothwell, 1993). Single pulse MEPs are used in our studies to precisely monitor 
changes in cortical excitability before and after pharmacological and/or non-invasive brain 
stimulation interventions. Apart from single-pulse TMS, we also used other single and paired 
pulse TMS protocols to explore various parameters of intracortical and corticospinal excitability, 
such as, active and resting motor thresholds (MTs), input-output (I-O) curves, I-waves, short 
latency intracortical inhibition (SICI), intracortical facilitation (ICF), and cortical silent period (CSP) 
(Fuhr et al., 1991, Kujirai et al., 1993, Ziemann and Rothwell, 2000, Abbruzzese and Trompetto, 
2002). 
In our studies, TMS was also used as plasticity-inducing protocol combined with peripheral nerve 
stimulation (see section 1.2.3).  
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1.3.2. Transcranial direct current stimulation  
 
Transcranial direct current stimulation is a non-invasive brain stimulation technique that can 
induce long lasting changes in cortical excitability. Current applied during tDCS is subthreshold, 
therefore unable to elicit action potentials (Nitsche and Paulus, 2000). The induced weak electric 
current penetrates through the skull and affects neuronal populations under the stimulation 
electrodes by shifting their resting membrane potential to the direction of de- or 
hyperpolarization, therefore making them more or less likely to be excited. These excitability 
changes depend on electrode polarity and can outlast the stimulation duration. Anodal 
stimulation induces depolarization and higher excitability, whereas cathodal tDCS has the 
opposite, hyperpolarizing effect (Nitsche and Paulus, 2001, Nitsche et al., 2003b, Nitsche et al., 
2008), when applied within the limits of standard protocols. Similar polarity-dependent long-
lasting effects have been shown before in slice and animal experiments (Bindman et al., 1964, 
Purpura and McMurtry, 1965).  
Pharmacological studies show that tDCS after-effects are NMDA receptor- and calcium-
dependent (Nitsche et al., 2003a). Administration of NMDA receptor antagonists or Ca2+ channel 
blockers abolish tDCS-induced plasticity (Liebetanz et al., 2002, Nitsche et al., 2003a), indicating 
that tDCS after-effects share similarities with LTD and LTP induction mechanisms in animal 
studies (Lisman, 2001), and alter the strength of glutamatergic synapses. 
1mA tDCS has been widely used in research as well as clinical studies. The current intensity and 
duration has been increased in numerous more recently conducted studies, based on the 
assumption that this will result in desired longer/stronger stimulation after-effects. Although 
several studies demonstrated clinical or cognitive effects of 2mA tDCS (Fregni et al., 2006a, 
Fregni et al., 2006b, Brunoni et al., 2011, Bueno et al., 2011, Brunelin et al., 2012), its impact on 
cortical excitability has not yet been explored physiologically.  
In all our studies, direct current was applied through pairs of saline-soaked surface sponge 
electrodes and delivered by a battery-driven constant current stimulator. One electrode was 
fixed over the motor cortex (the area representing the FDI or ADM muscle, as identified by TMS) 
and the return electrode was fixed contralaterally, over the right supraorbital area. The current 
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intensity was 1 or 2mA, applied for 9 (1mA cathodal tDCS), 13 (1mA anodal tDCS) or 20 minutes 
(2mA cathodal/anodal tDCS, 1mA cathodal tDCS) in the different studies, inducing after-effects 
lasting for about one hour after stimulation end.  
 
1.3.3. Paired associative stimulation  
 
Paired associative stimulation is a technique which combines a TMS pulse with low-frequency 
electric suprathreshold peripheral nerve stimulation, inducing neuroplastic changes, similar to 
spike-timing dependent plasticity (STDP). STDP is thought to be the underlying mechanism of 
learning/memory processes (Caporale and Dan, 2008). The direction of PAS-induced cortical 
excitability changes depends on the interstimulus interval between peripheral and TMS pulses. 
The peripheral stimulus is applied first and is followed by the TMS pulse. If the TMS pulse is 
applied 20-25ms after the peripheral stimulus (approximately the time the latter reaches M1), 
synchronous activation of the motor neurons occurs through somatosensory and motor cortical 
connections and facilitatory plasticity is induced. In contrast, when the TMS pulse is applied less 
than 20ms after the peripheral stimulus, it precedes the arrival of the peripheral pulse, therefore 
asynchronous activation of the above mentioned connections results in inhibitory plasticity 
(Stefan et al., 2000, Stefan et al., 2002, Wolters et al., 2003).  
PAS after-effects share some characteristics with those of tDCS, as they are also NMDA receptor 
and calcium dependent (Stefan et al., 2002, Wolters et al., 2003) and therefore thought to be 
LTP- and LTD-like. Unlike tDCS, which affects a big population of neurons under relatively large 
stimulation electrodes, PAS is thought to be focal and synapse-specific, affecting only small, 
specific population of neurons.  
In our experiments, the peripheral electric pulse was delivered over the right ulnar nerve at the 
level of the wrist at an intensity of 300% of the sensory perceptual threshold, followed by a TMS 
pulse over the M1 representation of the abductor digiti minimi muscle at ISIs of 10ms (PAS10) or 
25ms (PAS25) at a frequency of 0.05Hz. After PAS10, the asynchronous arrival of two pulses 
induced inhibitory plasticity, while after PAS25 their synchronous arrival to the motor cortex 
resulted in facilitatory plasticity (Stefan et al., 2002, Wolters et al., 2003).  
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1.4. Neuromodulators  
 
Neuromodulators are a class of neurotransmitters with specific features. Depending on 
postsynaptic receptor composition, cortical background activity, and dosage, amongst other 
factors, they can elicit either excitatory or inhibitory actions on cortical neurons and also 
modulate the release of other neurotransmitters (serotonin, dopamine, acetylcholine, etc). 
Recent studies suggest that synaptic plasticity does not always depend only on the pre-and 
postsynaptic neuronal activity, but also on the presence of neuromodulators (Malenka and Bear, 
2004). Unlike classical chemical synapses, where the presynaptic neuron directly affects the 
target cell, neuromodulatory synapses regulate relatively large neuronal populations and are 
believed to be important for learning and memory. Neuromodulators have been shown to 
influence LTP as well as LTD in animal and slice experiments in a non-linear manner (Kojic et al., 
1997, Fujii et al., 2000, Matsuyama et al., 2000, Fujii and Sumikawa, 2001b, Mori et al., 2001, 
Huang et al., 2004b, Ge and Dani, 2005, Kemp and Manahan-Vaughan, 2005, Huang and Kandel, 
2007, Luo et al., 2008, Costa et al., 2012, Park et al., 2012). 
Human and animal studies have demonstrated an impact of the above-mentioned 
neuromodulatory substances on cognitive processes, motor functions, motor learning, attention, 
working and episodic memories (Provost and Woodward, 1991, Knecht et al., 2004, Winters and 
Bussey, 2005, Floel et al., 2008, Heishman et al., 2010, Mocking et al., 2012). Moreover, several 
neurological disorders show altered neuromodulator levels that usually lead to deficits in 
cognitive functions (Parkinson’s disease, schizophrenia, Alzheimer’s disease, Lewy body 
dementia, depression, etc), whose physiological basis might be impact of neuromodulators on 
plasticity.  
In recent years several human studies were conducted using non-invasive brain stimulation 
techniques and pharmacological interventions to study the impact of neuromodulatory systems 
on different types of plasticity (Kuo et al., 2007, Kuo et al., 2008, Monte-Silva et al., 2009, 
Nitsche et al., 2009, Monte-Silva et al., 2010b, Thirugnanasambandam et al., 2012). In the 
studies presented in this thesis, we used different doses of pharmacologic agents to induce 
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alterations of cholinergic and serotonergic activity and different brain stimulation protocols to 
induce focal and non-focal plasticity in healthy human subjects.  
 
1.4.1. Serotonin  
 
The serotonergic system is one of the most important neuromodulatory systems in animals and 
humans, involved in many vital processes such as learning, memory, circadian rhythms and pain 
perception (Geyer, 1996, Hasbroucq et al., 1997, Jacobs and Fornal, 1997, Morin, 1999, Bert et 
al., 2008). Serotonin (5-HT) modulates neurotransmission by means of 5-HT receptors, which are 
a group of ligand-gated ion channels (5-HT3) and G-protein coupled receptors (5-HT1, 5HT-2, 
5HT-4, 5HT-5, 5HT-6, and 5HT-7) (Nichols and Nichols, 2008). 5-HT receptor activation has been 
shown to modulate glutamate-and GABA-mediated neurotransmission (Ciranna, 2006), as well 
as to affect LTP and LTD induction (Kojic et al., 1997, Mori et al., 2001, Ryan et al., 2008). 
Serotonin also affects cholinergic, dopaminergic, and GABAergic neuromodulatory systems, that 
impact on plasticity and cognition (Consolo et al., 1994, Roerig and Katz, 1997, Gobert and 
Millan, 1999, Zaniewska et al., 2009).  
Selective serotonin reuptake inhibitors (SSRIs) are one of the major classes of antidepressant 
drugs that inhibit the reuptake of serotonin by the presynaptic cell, therefore increasing its 
effect on the postsynaptic neuron (Stahl, 1998). Depression is thought to be affected by altered 
brain plasticity (Garcia, 2002, Christoffel et al., 2011) on which distress has a major impact (Caspi 
et al., 2003). Studies with animal models have shown that stress inhibits LTP and facilitates LTD 
induction (Foy et al., 1987, Xu et al., 1997, Rocher et al., 2004) and could be prevented by 
chronic SSRI administration (Holderbach et al., 2007). Serotonin enhancers have a positive effect 
on motor and cognitive functions in patients as well as healthy individuals (Dam et al., 1996, 
Loubinoux et al., 1999, Loubinoux et al., 2002a, Loubinoux et al., 2002b, Loubinoux et al., 2005, 
Chollet et al., 2011). This positive impact might be caused by serotoninergic modulation of 
cortical plasticity.  
Recent studies in human subjects have shown that serotonin has a facilitatory impact on 
neuroplasticity. Single-dose SSRI administration enhanced anodal tDCS-induced facilitatory 
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plasticity and converted cathodal tDCS-induced inhibitory plasticity into facilitation (Nitsche et 
al., 2009). SSRI intake also enhanced facilitatory plasticity of early visual-evoked potentials and 
trendwise shifted inhibitory plasticity towards facilitation (Normann et al., 2007).  
Other neuromodulators, such as dopamine, acetylcholine, and nicotine are characterized by a 
so-called “focusing effect” on focal, synapse-specific facilitatory plasticity (Kuo et al., 2007, Kuo 
et al., 2008, Monte-Silva et al., 2010b, Thirugnanasambandam et al., 2012), which explains their 
positive effect on processes that require consolidation of learning and memory-related cognitive 
functions, via increase of the signal-to-noise ratio. Unlike the above-mentioned 
neuromodulatory systems, data about the serotoninergic impact on focal neuroplasticity are 
missing. In accordance to the previous studies, we hypothesize that serotoninergic system 
activation should enhance focal facilitatory plasticity and abolish focal inhibitory plasticity or 
convert it into facilitation.  
  
1.4.2. Nicotine  
 
The cholinergic system is involved in attention, short-term memory, arousal and sensory 
perception (Provost and Woodward, 1991, Hahn and Stolerman, 2002, Kumari et al., 2003, 
Jubelt et al., 2008, Heishman et al., 2010). Pathological states of the cholinergic system are 
observed in schizophrenia and Alzheimer’s disease (Jones et al., 1992, White and Levin, 1999). 
Cholinergic modulation is accomplished by means of two receptor types: nicotinic (nAChRs) and 
muscarinic acetylcholine receptors (mAChRs). NAChRs are ligand-gated cation channels that are 
non-selectively activated by acetylcholine and nicotine (Burnashev, 1998, Dajas-Bailador and 
Wonnacott, 2004). Besides addictive properties, several studies demonstrate positive effects of 
nicotine on cognitive functions (Hahn et al., 2002, Hahn and Stolerman, 2002, Jubelt et al., 2008, 
Froeliger et al., 2009, Mocking et al., 2012). Nicotine withdrawal often causes impairments of 
neuroplasticity and working/verbal memory in smoking individuals, while nicotine re-
administration restores these functions (Jacobsen et al., 2005, Cole et al., 2010, Grundey et al., 
2012a). 
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The physiological mechanism for the nicotinic modulation of cognition is thought to be its impact 
on neuroplasticity, accomplished by activation of nAChRs.  and nAChRs modulate the 
permeability of Ca2+ ions, involved in LTD/LTP induction (Burnashev, 1998, Lisman, 2001). In 
accordance, several animal and slice studies have shown that nicotinic receptor activation 
results in LTP facilitation (Matsuyama et al., 2000, Fujii and Sumikawa, 2001a, Welsby et al., 
2006, Nakauchi et al., 2007), reversal of GABAergic inhibition of LTP (Fujii et al., 2000) and LTD 
enhancement (Fujii and Sumikawa, 2001b, Ge and Dani, 2005).  
Recent studies explored the nicotinic impact on cortical excitability and plasticity in humans. 
Global cholinergic activation preserved and prolonged both focal and non-focal inhibitory 
plasticity and increased focal, but abolished non-focal inhibitory plasticity. Nicotinic receptor 
activation induced similar effect for LTP-like plasticity, but LTD-like plasticity was abolished in 
healthy non-smoking subjects (Kuo et al., 2007, Thirugnanasambandam et al., 2012). These 
studies show a “focusing effect” of cholinergic activation on LTP-like plasticity, which can explain 
the positive cholinergic impact on cognition. 
Nicotinic receptor activation was accomplished by application of nicotine patches in the above-
mentioned study (Thirugnanasambandam et al., 2012), which non-specifically activates all 
nicotinic receptors, therefore contribution of specific nicotinic receptor subtypes to nicotinic 
modulation of neuroplasticity still remains unclear. Given that after-effects induced by tDCS and 
PAS are calcium-dependent (Stefan et al., 2002, Nitsche et al., 2003a), it can be hypothesized 
that nicotinic receptors with calcium channel properties ( and ) are involved. Similar to 
the effect of nicotine, activation of these receptors should result in abolishment of non-focal 
plasticity and preservation of focal facilitatory plasticity in non-smoking humans.  
 
1.5. Aim of the thesis  
 
In the studies presented in this thesis, we aimed to explore the impact of modified brain 
stimulation protocols and neuromodulatory systems on stimulation-induced plasticity in 
humans. In the first study, we explored the intracortical and corticospinal effects of clinically 
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used 2mA direct current stimulation. We used several single and paired-pulse TMS protocols 
(single-pulse MEPs, motor thresholds, I-O curve, I waves, short-latency intracortical inhibition 
and intracortical facilitation, cortical silent period) to study its impact on various 
neurophysiological parameters. Based on the generally accepted assumption that stronger 
stimulation results in larger effects of tDCS (Nitsche and Paulus, 2000), we expected a positive 
correlation between intensity of stimulation and strength and duration of after-effects.  
In the second study, we aimed to deepen our knowledge about serotoninergic modulation of 
neuroplasticity, specifically, its impact on PAS-induced focal plasticity. As PAS-induced plasticity 
is thought to share similarities with spike timing-dependent plasticity, results of this study could 
help us to explain the mechanisms of the positive serotoninergic impact on cognition and 
learning as well as on clinical symptoms in medical conditions, characterized by compromised 
and maladaptive plasticity (stroke, depression). For this purpose, we applied an experimental 
design similar to a previous study (Nitsche et al., 2009), with the only exception of the specific 
brain stimulation protocol (we administered PAS instead of tDCS). We expected that serotonin 
would shift plasticity towards an excitability enhancement.  
In the last study, our goal was to explore the contribution of nicotinic acetylcholine receptor 
subtypes to neuroplasticity. Previous studies demonstrated an impact of global cholinergic and 
nicotinic receptor activation on stimulation-induced plasticity (Kuo et al., 2007, 
Thirugnanasambandam et al., 2012), but knowledge about the involvement of specific receptors 
in this process is limited. Therefore we aimed to focus on dose-dependent effect of  nAChRs 
on both non-focal and focal types of plasticity. To that end, we administered different doses of 
the  nicotinic receptor partial agonist varenicline on both, non-focal and focal plasticity-
inducing brain stimulation protocols (tDCS and PAS). We expected that high drug dosages should 
demonstrate a focusing effect, similar to nicotine (Thirugnanasambandam et al., 2012), by 
preserving PAS-induced focal excitatory plasticity in non-smoking healthy individuals. 
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Human Motor Cortex 
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Running title: Impact of varenicline on neuroplasticity 
 
Abstract 
The neuromodulator nicotine alters cognitive functions in animals and humans most likely by 
modification of brain plasticity. In the human brain, it alters plasticity induced by transcranial 
direct current stimulation (tDCS) and paired associative stimulation (PAS), probably by 
interference with calcium-dependent modulation of the glutamatergic system. We aimed to test 
this hypothesis further by exploring the impact of the  nicotinic receptor partial agonist 
varenicline, which has calcium channel properties, on focal and non-focal plasticity, induced by 
PAS and tDCS, respectively. We administered low (0.1mg), medium (0.3mg) and high (1.0mg) 
single doses of varenicline or placebo medication before PAS or tDCS on the left motor cortex of 
25 healthy non-smoking individuals. Corticospinal excitability was monitored by single-pulse 
transcranial magnetic stimulation (TMS)-induced motor evoked potential (MEP) amplitudes up 
to 36 hours after plasticity induction. Whereas low-dose varenicline had no impact on 
stimulation-induced neuroplasticity, medium-dose varenicline preserved only focal excitatory 
plasticity. High-dose application preserved cathodal tDCS-induced excitability diminution and 
focal facilitatory plasticity induced by excitatory PAS, but abolished anodal tDCS- and inhibitory 
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PAS-induced changes in excitability. These results are comparable to the impact of nicotine 
receptor activation and might help to further explain the involvement of specific receptor 
subtypes in the nicotinic impact on neuroplasticity and cognitive functions in humans.  
 




Smoking tobacco is one of the leading risks to human health (Peto et al., 1992, Doll et al., 2005). 
Nicotine is the main neuroactive component of tobacco responsible for physical dependence 
and addiction. Besides addictive properties, many studies demonstrate positive effects on 
cognition. Human and animal studies have shown that nicotine improves attention, motor 
functions, working and episodic memories (Provost and Woodward, 1991, Hahn et al., 2002, 
Hahn and Stolerman, 2002, Kumari et al., 2003, Jubelt et al., 2008, Froeliger et al., 2009, 
Heishman et al., 2010, Mocking et al., 2012). Nicotine also improves learning, attention and 
perception in patients suffering from Alzheimer’s disease (Jones et al., 1992, Wilson et al., 1995, 
White and Levin, 1999). Nicotine withdrawal is often associated with impairments of working 
and verbal memory and neuroplasticity, while nicotine re-administration restitutes these 
functions in smoking individuals (Jacobsen et al., 2005, Cole et al., 2010, Grundey et al., 2012a).  
The neurophysiological basis for the nicotinic effects on cognition is hypothesized to be its 
impact on cortical excitability and plasticity, controlled by activation of  and nicotinic 
acetylcholine (nAChR) receptors. These are ligand-gated ion channels (Burnashev, 1998, Dajas-
Bailador and Wonnacott, 2004), which modulate the permeability of Ca2+ ions and are centrally 
involved in plasticity induction (Lisman, 2001). In accordance, animal studies have demonstrated 
that activation of nicotinic receptors results in LTP facilitation (Matsuyama et al., 2000, Fujii and 
Sumikawa, 2001a, Welsby et al., 2006, Nakauchi et al., 2007), reversal of GABAergic inhibition of 
LTP (Fujii et al., 2000) as well as LTD enhancement (Fujii and Sumikawa, 2001b, Ge and Dani, 
2005).  
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Recently, studies in humans demonstrated that global cholinergic activation increases focally, 
but abolishes non-focally induced LTP-like plasticity, whereas it preserves and prolongs both 
focal and non-focal LTD-like plasticity. For nicotine, a similar effect was seen for LTP-like 
plasticity, but LTD-like plasticity was abolished by this substance in non-smoking healthy humans 
(Kuo et al., 2007, Thirugnanasambandam et al., 2012). These results show a partial dissociation 
of the impact of global cholinergic activation and nicotinic receptor activation on plasticity. 
Furthermore, the “focusing effect” on LTP-like plasticity might explain a beneficial impact on 
cognition. 
In these studies, focal and non-focal plasticity was induced by transcranial direct current 
stimulation (tDCS) and paired associative stimulation (PAS), respectively. Both, tDCS and PAS are 
non-invasive brain stimulation techniques inducing long-lasting changes of cortical excitability 
which are Ca2+ and NMDA receptor-dependent (Nitsche and Paulus, 2000, Stefan et al., 2000, 
Nitsche and Paulus, 2001, Stefan et al., 2002, Nitsche et al., 2003a, Nitsche et al., 2003b, Wolters 
et al., 2003). Neuroplastic changes induced by tDCS are non-focal and affect neuronal 
populations beneath the relatively large stimulation electrodes via subthreshold resting 
membrane potential modulation (Purpura and McMurtry, 1965, Nitsche et al., 2007, Nitsche et 
al., 2008). In contrast, plasticity induced by PAS is presumed to be focal, synapse-specific and 
timing-dependent, affecting only selective neuronal populations. During PAS, a repetitive electric 
pulse to a peripheral nerve is combined with suprathreshold transcranial magnetic stimulation 
(TMS)-pulse over the corresponding area of the primary motor cortex. The target group of 
somatosensory-motor cortical synaptic connections, is activated synchronously or 
asynchronously by combined peripheral and TMS pulses, depending on the interstimulus interval 
(ISI), resulting in excitatory or inhibitory after-effects (Stefan et al., 2000). PAS is thought to be 
closely linked to learning and memory processes, as its mechanism resembles some 
characteristics of spike timing-dependent plasticity (STDP) (Stefan et al., 2002, Wolters et al., 
2003, Caporale and Dan, 2008).  
Beyond unspecific activation of nicotinic receptors by nicotine, not much is known about the 
contribution of nicotinic receptor subtypes on neuroplasticity in humans. Given that tDCS and 
PAS induce calcium-dependent plasticity, it can be speculated that specifically nicotinic receptors 
with calcium channel properties might be involved. In the present study, we aimed to explore 
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the contribution of  receptors on non-invasive brain stimulation-induced focal and non-focal 
plasticity in human non-smokers via application of varenicline. Varenicline is an effective 
smoking cessation agent (Coe et al., 2005), which is a high-affinity partial agonist to  and full 
agonist to  nAChRs (Mihalak et al., 2006). We hypothesized that effective dosages of the drug 
should, similar to the effect of nicotine (Thirugnanasambandam et al., 2012), abolish tDCS-
induced non-focal plasticity and preserve PAS-induced focal excitatory plasticity in non-smoking 
healthy subjects. 
 
Materials and methods 
 
Subjects  
Twenty-five healthy non-smoker subjects aged 24.8 ± 4.4 years (11 males/15 females) were 
recruited. Two subjects did not finish the experiment. All subjects were right-handed according 
to the Edinburgh handedness inventory (Oldfield, 1971). None of them took any medication, had 
a history of a neuropsychiatric or medical disease, present pregnancy, or metallic head implants. 
All volunteers gave written informed consent and were compensated for participation. The 
investigation was approved by the Ethics Committee of the University of Göttingen, and 
conforms to the principles laid down in the Declaration of Helsinki.  
 
Transcranial Direct Current Stimulation 
Twelve subjects aged 24.4 ± 4.7 years (4 males/8 females) participated in tDCS experiment. 
Direct current was delivered by a battery-driven constant current stimulator (neuroConn GmbH, 
Ilmenau, Germany) through a pair of rubber electrodes covered with saline-soaked sponges (5 x 
7 cm). The motor cortex electrode was fixed over the area representing the right abductor digiti 
minimi muscle (ADM) and the return electrode contralaterally above the right supraorbital area. 
Subjects received 1mA of either excitability-enhancing anodal tDCS for 13 minutes or excitability-
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diminishing cathodal tDCS for 9 minutes, which induces motor cortex excitability alterations 
lasting for about 1 h (Nitsche and Paulus, 2001, Nitsche et al., 2003b).  
 
Paired Associative Stimulation 
Twelve subjects 25 ± 4.4 years (6 males/6 females) participated in PAS experiment. The 
peripheral electric pulse over the right ulnar nerve at the level of the wrist at an intensity of 
300% of the sensory perceptual threshold was followed by a TMS pulse over the M1 
representation of the abductor digiti minimi muscle (ADM) at ISIs of 10ms (PAS10) or 25ms 
(PAS25) at a frequency of 0.05Hz. The peripheral electric pulse was delivered by a Digitimer D184 
multipulse stimulator (Digitimer, Welwyn Garden City, United Kingdom). The TMS pulse was 
delivered by a Magstim 200 stimulator with an intensity to elicit single pulse MEPs with peak-to-
peak amplitudes of on average 1 mV. The participants were instructed to silently count the 
number of pulses they received at their wrist during the whole stimulation duration to 
guarantee sufficient attention to the procedure, which has been shown to be crucial to obtain 
the desired after-effects (Stefan et al., 2000, Stefan et al., 2004). 
 
Pharmacological Interventions 
Low (0.1mg), medium (0.3mg) or high (1.0mg) dosages of varenicline or 0.5 mg placebo were 
administered in form of two-piece gelatin capsules (size 2, 18mm length, 6.35mm external 
diameter) 3 hours before the start of the experimental session, allowing the verum drug to 
induce a maximum plasma level and produce prominent effects in the central nervous system 
(Faessel et al., 2006, Obach et al., 2006, Faessel et al., 2010). 
 
Monitoring of motor cortical excitability 
MEPs were recorded from the right ADM by single-pulse TMS over the corresponding left 
primary motor cortex, conducted by a Magstim 200 magnetic stimulator (Magstim, Whiteland, 
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Dyfed, United Kingdom) with a figure-of-eight magnetic coil (diameter of one winding – 70mm; 
peak magnetic field - 2.2 T). The coil was held tangentially to the skull, with the handle pointing 
backwards and laterally at 450 from the midline. The hotspot was defined as the optimal coil 
placement, where the TMS pulse resulted consistently in the largest MEPs of the contralateral 
ADM. Surface MEPs were recorded from the right ADM with Ag-AgCl electrodes in a belly-
tendon montage. The signals were amplified, and band-pass filtered (2Hz to 2kHz, sampling rate, 
5kHz), digitized with a micro 1401 AD converter (Cambridge Electronic Design, Cambridge, UK), 
controlled by Signal Software (Cambridge Electronic Design, v. 2.13), and stored for offline 
analysis.  
 
Experimental procedures  
A unique sequence of experimental sessions was randomly generated individually for each 
subject, which did not match any previously generated one for other subjects. The participants 
were seated in a comfortable chair with head and arm rests. In the beginning, the hotspot was 
identified by TMS and then the stimulation intensity was adjusted to elicit single pulse MEPs 
with peak-to-peak amplitudes of on average 1 mV. Then twenty-five MEPs were recorded for the 
determination of first baseline. After baseline recording, varenicline or placebo medication was 
administered. Three hours after intake of medication, a second baseline was recorded to 
monitor for a possible impact of the drug alone on cortical excitability (baseline 2), and TMS 
intensity was adjusted, if necessary (baseline 3). After that procedure, the respective plasticity 
induction protocol was administered (cathodal tDCS, anodal tDCS, PAS10 or PAS25) and twenty-
five MEPs were recorded at time points of 0, 5, 10, 15, 20, 25, 30, 60, 90 and 120 minutes after 
tDCS. Further TMS measurements were conducted in the evening of the same day (SE), next 
morning, at ~9:00 AM (NM), next noon, at ~12:00PM (NN) and next evening, at ~6:00PM (NE) 
(Figure 1). To keep the EMG electrodes and TMS coil at the same place for later measurements, 
their positions were marked with a waterproof pen. The minimum period between two 
consecutive experimental sessions for a single subject was seven days. Subjects were blinded for 
both, stimulation and medication conditions; the experimenter was blinded for the medication 
condition.  
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Analysis and statistics 
The experimenter was unblinded after finishing data collection and analysis. The individual 
means of 25 MEP amplitudes were calculated at each time point for every subject and the post-
tDCS mean MEP amplitudes were normalized to the respective mean baseline MEP amplitudes 
(quotient of post-stimulation MEPs vs pre-stimulation values: baseline 2, or, if TMS intensity had 
to be adjusted, baseline 3). Then the grand averages for each time point were calculated. A 
repeated measures ANOVA was performed on the above-mentioned data separately for tDCS 
and PAS experiments, using MEP amplitude as the dependent variable and medication, 
stimulation type and time course as within-subject factors. The Mauchly test of sphericity was 
performed and the Greenhouse-Geisser correction applied when necessary. In case of significant 
results of the ANOVA, exploratory post hoc comparisons were performed using Student’s t tests 
(paired samples, two-tailed, p < 0.05, not corrected for multiple comparisons) between the MEP 
amplitudes before and after intervention within one experimental condition and between the 
single time points (medication vs placebo) within the same stimulation condition.  
To compare main effects of different dosages of varenicline on plasticity, averaged MEPs for the 
first 30 minutes after stimulation were calculated for each subject per experimental session and 
normalized to baseline 2 (or baseline 3, if TMS intensity was adjusted). Then, these averaged 
MEP values for each dosage condition were compared with the respective placebo condition by 
Student’s t-tests (paired samples, two-tailed, p < 0.05, not corrected for multiple comparisons).  
To exclude differences between baseline values of different conditions, and also between first, 
second and third baseline values, the respective values were compared using Student’s t-tests 
(paired samples, two-tailed, p < 0.05, not corrected for multiple comparisons).  
 
Results 
All subjects tolerated the procedure well. Only five of them reported slight dizziness, lasting for 
about one hour after drug intake, which is a mild side effect of varenicline.  
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Two participants (one from tDCS and one from PAS experiment) left the study after first 
experimental day due to time constraints.  
The average baseline MEP values did not significantly differ between groups as revealed by 
Student’s t tests (paired samples, two-tailed, p > 0.05). Varenicline alone did not have any 
impact on cortical excitability at any dosage, as revealed by Student’s t tests between first, 
second, and third baseline values (paired samples, two-tailed, p > 0.05) (Table 1).  
 
Effect of varenicline on tDCS-induced plasticity 
The ANOVA revealed significant main effects of STIMULATION (F(1)=117.900; p<0.001), 
MEDICATION x STIMULATION (F(3)=5.050; p=0.005), STIMULATION x TIME (F(14)=10.013; 
p<0.001) and MEDICATION x STIMULATION x TIME (F(42)=2.375; p<0.001) interactions (for 
details see table 2).   
Post-hoc Student’s t tests show that in the placebo and low dose varenicline medication 
conditions, MEPs were significantly enhanced for 60 minutes after anodal and reduced after 
cathodal tDCS as compared to respective baseline values. MEPs obtained under low-dose 
varenicline did not differ from those under placebo medication at any time point. Medium dose 
varenicline abolished both anodal and cathodal tDCS-induced after effects. Here MEP amplitudes 
did not differ from baseline values at any time point, and MEPs were significantly altered as 
compared to the respective placebo medication conditions for up to 30 min after tDCS. Under 
high-dose varenicline, the cathodal tDCS-induced excitability diminution was significant versus 
baseline until the evening after tDCS, but did not differ significantly from the placebo medication 
condition. For anodal tDCS, the respective excitability enhancement was initially abolished, and 
MEPs were significantly smaller than those under placebo medication for the first 10 min after 
tDCS. However, MEPs were enhanced versus baseline between 25 and 30 minutes after plasticity 
induction (Figure 2 A,B).  
For the effects of different dosages of varenicline on tDCS-induced plasticity with regard to the 
grand average calculated for the first 30 min after intervention, medium dose of varenicline had 
a significant abolishing effect on both excitability-enhancing and -diminishing non-focal 
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plasticity, as revealed by respective student’s t-tests (Student’s t test, paired samples, two-tailed, 
p<0.01). Furthermore, the anodal tDCS-induced excitability enhancement was abolished by high 
dose varenicline (Student’s t test, paired samples, two-tailed, p=0.02). Low dose of varenicline 
showed no significant differences from the respective placebo medication conditions (Student’s 
t test, paired samples, two-tailed, p > 0.05) (Figure 4). 
 
Effect of varenicline on PAS-induced plasticity 
The ANOVA revealed significant main effects of STIMULATION (F(1)=19.134; p=0.003), 
STIMULATION x TIME (F(14)=19.064; p<0.001) and MEDICATION x STIMULATION x TIME 
(F(42)=1.476; p=0.035) interactions (table 2). 
Post-hoc Student’s t tests show that MEPs were significantly enhanced for about an hour after 
PAS25 in all medication conditions, and reduced after PAS10 in placebo and low dose varenicline 
condition as compared to respective baseline values. Medium and high doses of varenicline 
abolished PAS10-induced after effects. Here MEP amplitudes did not differ from baseline values 
at any time point, and MEPs were significantly altered as compared to the respective placebo 
medication conditions for up to 60 min after PAS administration. In all other conditions, MEPs 
obtained after varenicline administration did not differ from those under placebo medication at 
any time point (Figure 3 A,B). 
For the effects of different dosages of varenicline on PAS-induced plasticity with regard to the 
grand average calculated for the first 30 min after intervention, medium and high doses of 
varenicline have a significant abolishing effect on PAS10-induced focal inhibitory plasticity as 
revealed by the respective student’s t-tests (Student’s t test, paired samples, two-tailed, p<0.001 
and p=0.01, respectively). The other conditions showed no significant differences from the 








The results of this study show that activation of nicotinic  and possibly,  receptors has 
specific and dosage-dependent effects on neuroplasticity in healthy human non-smoking 
individuals. Low-dosage varenicline did not affect plasticity. In contrast, medium dose of the 
drug preserved only focal LTP-like plasticity. Under high dosages of the drug, non-focal LTD-like 
and focal LTP-like effects were preserved, but non-focal LTP-like and focal LTD-like plasticity 
were compromised. The results obtained under medium-dosage varenicline are fairly identical to 
those of a previous study, which explored the impact of nicotine on tDCS-induced plasticity (Kuo 
et al., 2007, Thirugnanasambandam et al., 2012). Therefore, we presume that the focusing effect 
of nicotine on facilitatory plasticity is at least partially caused by  receptors. As the MEP 
amplitudes alone were not affected by any dose of varenicline, a direct influence of the drug on 
cortical excitability can be ruled out.  
 
Proposed Mechanisms of Action 
After-effects of tDCS and PAS are NMDA receptor- and Ca2+-dependent (Stefan et al., 2002, 
Nitsche et al., 2003a, Wolters et al., 2003). Since  and nAChRs are ligand-gated ion 
channels (Burnashev, 1998, Dajas-Bailador and Wonnacott, 2004), they might affect LTP and LTD 
induction by an alteration of membrane permeability to Ca2+ ions (Lisman, 2001). Indeed, in 
animal slice experiments, agonists of the respective receptors have a prominent impact on 
stimulation-induced plasticity. Nicotine has been shown to enhance LTP by postsynaptically 
activating  nicotinic receptors in the rat dentate gyrus (Welsby et al., 2006), and facilitates 
NMDA-dependent LTP induction (Yamazaki et al., 2005, Yamazaki et al., 2006a, Yamazaki et al., 
2006b, Griguoli et al., 2013, Prestori et al., 2013). In another study, activation of both,  and 
 nicotinic receptors was essential for LTP induction (Matsuyama and Matsumoto, 2003). Since 
activation of nAChRs increased intracellular Ca2+ in several studies (Chavez-Noriega et al., 1997, 
Chavez-Noriega et al., 2000, Khiroug et al., 2003, Karadsheh et al., 2004, Fayuk and Yakel, 2005, 
2007, Jia et al., 2010), this effect is most probably accomplished by calcium concentration 
alterations.   
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At first glance, the impact of nicotinic receptor enhancement on plasticity in the present 
experiment is not completely compatible with the direction of effects obtained in the above-
mentioned animal experiments, especially with regard to LTD-induction. However, the key for 
understanding the results might be the non-linear impact of calcium on plasticity. Whereas low 
intraneuronal calcium enhancement induces LTD, high concentrations induce LTP. In between, a 
“no man´s land” does exist, in which no plasticity results, and very high calcium concentrations 
might also prevent plasticity because of activation of hyperpolarizing potassium channels 
(Lisman, 2001, Misonou et al., 2004). Therefore, whereas both strains of experiments stress the 
role of nicotine receptors for plasticity, the reason for differently directed results of animal and 
human experiments might be different amounts of calcium influx caused by the respective 
receptor agonists, and plasticity induction procedures. 
The reason that low dosage varenicline, which are 10 times lower than the single oral dosage 
(1mg) administered in smokers to support cessation of tobacco consumption (Faessel et al., 
2010), had no significant effect on plasticity is most probably that this dosage did not suffice to 
activate nicotinic receptors to an amount at which these induce relevant intraneuronal calcium 
concentration alterations. The plasticity-abolishing effects of the medium and high dosages of 
the drug with regard to excitability-diminishing plasticity, and tDCS-induced facilitatory plasticity 
go in line with the results of previous studies (Grundey et al., 2012b, Thirugnanasambandam et 
al., 2012), where global nicotinic receptor activation resulted in abolishment of these kinds of 
plasticity. Therefore, it is plausible that at least a part of the impact of nicotine on plasticity is 
driven by and  receptors. As varenicline is a full agonist of  and potent partial agonist of 
 receptors, with a far greater affinity (4000-5000 fold) to  as compared to  receptors 
(Avalos et al., 2002, Jensen et al., 2005, Mihalak et al., 2006, Rollema et al., 2010), the 
receptor might have a larger relevance for the results. Due to the above-mentioned calcium 
hypothesis, the most probable explanation for the abolishment of LTD-like plasticity by the 
medium dosage of the drug is that here nicotinic receptor activation drove calcium 
concentrations in the respective “no man´s lands”. For the abolishment of the non-focal LTP-like 
plasticity induced by anodal tDCS under high-dosage varenicline, the same mechanism might 
apply. In contrast, the PAS25-induced excitability enhancement was not affected by any dose of 
varenicline. This can be explained by differences between the stimulation-inducing protocols. 
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Neuroplastic changes via tDCS are achieved by long-lasting, tonic depolarization of large 
population of neurons and activation of voltage-dependent Ca2+-channels, whereas PAS only 
affects small group of neurons and causes short-lasting depolarizations. Therefore the amount of 
intracellular calcium increase may be smaller with regard to PAS as compared to tDCS and not 
sufficient to induce significant changes in neuroplasticity (Thirugnanasambandam et al., 2012).   
This mechanism does however not explain the re-establishment of cathodal tDCS-induced LTD-
like plasticity under the high dosage of the drug. Here it could be speculated that an antagonistic 
effect of varenicline on the respective nicotinic receptor, which takes place for higher dosages of 
the drug, resulted in reduced calcium influx, and thus a restitution of plasticity. These 
mechanistic explanations are however hypothetical at present, and should be explored more 
directly in future studies in humans, and animal models. 
For the overall pattern of experimental results, varenicline applied in medium and high doses 
results in a focusing effect on facilitatory neuroplasticity, preserving focal, but abolishing non-
focal facilitatory plasticity, similar to global nicotinic and cholinergic system activation (Kuo et al., 
2007, Thirugnanasambandam et al., 2012). Such a focusing effect might be beneficial for task 
performance via enhancing the signal-to-noise ratio and can explain the positive nicotinic effect 
on cognitive functions (attention, working and episodic memory), where a stable processing of 
information is essential (Provost and Woodward, 1991, Kumari et al., 2003, Jubelt et al., 2008, 
Froeliger et al., 2009, Heishman et al., 2010, Mocking et al., 2012). Further behavioral 
experiments should be designed to explore this hypothesis.  
 
General remarks 
This study demonstrates that varenicline has a prominent impact on neuroplasticity in non-
smoking humans, which is similar to that of nicotine application. Besides being an effective 
smoking cessation agent, varenicline is also suggested to have therapeutic effect in patients 
suffering from Alzheimer’s Disease (Kem, 2000, Jensen et al., 2005, Mihalak et al., 2006) and 
patients with schizophrenia during smoking abstinence (Hong et al., 2011, Liu et al., 2011, Shim 
et al., 2012). From this perspective, exploring the role of specific receptors ( and possibly  
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too) in the nicotinic effect on cognition and neuroplasticity is important and should be further 
addressed in future studies.  
It has to be taken into account that the results of this study show only the impact of a single 
dose of varenicline on neuroplasticity. Many studies have shown that chronic exposure to 
nicotine can cause upregulation (Wonnacott, 1990, Buisson and Bertrand, 2001) and 
desensitization (Hsu et al., 1996, Fenster et al., 1997, Fenster et al., 1999) of nAChRs, therefore 
the effect of varenicline after chronic administration on neuroplasticity might be qualitatively 
different from that after an acute dose. This important aspect of nicotinic impact on 
neuroplasticity should also be explored in future studies.  
Recent studies have shown that neuroplasticity, as well as verbal and working memory functions 
are reduced in smoking individuals after nicotine withdrawal and restituted by nicotine re-
administration (Cole et al., 2010, Grundey et al., 2012a). Varenicline has also shown to improve 
working memory in nicotine abstinence (Patterson et al., 2009, Loughead et al., 2010). It might 
be interesting to explore if varenicline has similar restituting effects on plasticity, as shown for 
cognitive processes, in these individuals.  
 
Limiting Conditions 
A possible limitation to our study is that varenicline is an agonist with moderate affinity to 5-HT3 
serotonin receptors (Lummis et al., 2011). 5-HT3 receptors have a facilitatory impact on 
plasticity (Normann et al., 2007, Nitsche et al., 2009, Batsikadze et al., In Press). However, 
concentrations of therapeutic unbound varenicline in the brain are insufficient for activation of 
these receptors (Rollema et al., 2011). Moreover, in a recently conducted study, the serotonin 
reuptake inhibitor citalopram enhanced tDCS-induced LTP-like plasticity, and converted LTD-like 
plasticity into facilitation (Nitsche et al. 2009). These results are qualitatively different to those 
obtained in the present study. Varenicline has also an impact on D2/3 dopamine receptor 
binding and availability in rats (Crunelle et al., 2009, Crunelle et al., 2011, Crunelle et al., 2012) 
and GABAergic synaptic transmission (DuBois et al., 2013), which have a major impact on 
stimulation-induced plasticity. It should be noted that also for these transmitters and receptors, 
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pharmacological modulations resulted in effects which clearly differ from those obtained under 
varenicline (Nitsche et al., 2004, Kuo et al., 2008, Monte-Silva et al., 2009, Monte-Silva et al., 
2010). Nevertheless, in order to explore the complex interplay of neuromodulatory systems on 
nicotine-modulated plasticity, future studies should use approaches combining pharmacological 
interventions with neuroimaging.  
Another limitation is that the specific neurophysiological mechanisms underlying the nicotinic 
impact on various corticospinal and intracortical excitability parameters were not investigated. 
We did not perform these measures in the present study, because this would have made it 
impossible to explore the detailed time-course of plasticity. However, it would be important to 
explore the effect of varenicline on cholinergic activity e.g. by monitoring short-latency afferent 
inhibition (SAI) and on GABAergic and glutamatergic transmission by measuring short-latency 
intracortical inhibition (SICI) and intracortical facilitation (ICF) (Ziemann et al., 1996, Di Lazzaro et 
al., 2002, Di Lazzaro et al., 2005, Paulus et al., 2008), to unravel the physiological background of 
the respective effects. 
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Table 1. MEP amplitudes and stimulation intensity before and after varenicline administration. 
 
Shown are the mean MEP amplitudes ± S.D. and stimulation intensity (percentage of maximum 
stimulator output, %MSO) mean ± S.D. of baselines 1, 2 and 3. The intensity of TMS was adjusted 
to elicit MEPs with peak-to-peak amplitude of ~1mV (baseline 1). A second baseline (baseline 2) 
was recorded three hours after varenicline or placebo intake to determine the impact of the 
drug on cortical excitability and adjusted if necessary (baseline 3). Student´s t-tests revealed no 
significant differences between conditions (p > 0.05). 




0.1mg 0.95 ± 0.07 
1.00 ± 0.11 
0.92 ± 0.06 
0.95 ± 0.07 
0.95 ± 0.07 
0.94 ± 0.17 
0.98 ± 0.12 
0.94 ± 0.09 
0.96 ± 0.13 
0.96 ± 0.14 
0.98 ± 0.11 





0.1mg 53.67 ± 6.76 
53.58 ± 7.25 
54.00 ± 7.39 
53.50 ± 7.18 
53.67 ± 6.76 
53.58 ± 7.25 
54.00 ± 7.39 
53.50 ± 7.18 
53.67 ± 6.76 
53.92 ± 7.63 
54.00 ± 7.22 






0.1mg 0.99 ± 0.13 
0.98 ± 0.10 
0.98 ± 0.09 
0.92 ± 0.08 
0.92 ± 0.17 
1.00 ± 0.25 
1.01 ± 0.42 
0.97 ± 0.12 
0.95 ± 0.13 
0.95 ± 0.07 
0.98 ± 0.09 





0.1mg 53.67 ± 6.81 
52.83 ± 6.81 
53.33 ± 7.48 
53.25 ± 7.90 
53.67 ± 6.81 
52.83 ± 6.81 
53.33 ± 7.48 
53.25 ± 7.90 
53.83 ± 6.79 
52.67 ± 6.85 
53.42 ± 7.51 






0.1mg 0.96 ± 0.12 
1.03 ± 0.10 
1.00 ± 0.12 
0.97 ± 0.08 
0.95 ± 0.29 
0.99 ± 0.18 
1.00 ± 0.16 
0.99 ± 0.07 
1.01 ± 0.10 
0.96 ± 0.11 
1.00 ± 0.08 





0.1mg 51.00 ± 9.05 
52.17 ± 9.33 
50.83 ± 9.46 
51.83 ± 9.23 
51.00 ± 9.05 
52.17 ± 9.33 
50.83 ± 9.46 
51.83 ± 9.23 
51.33 ± 9.82 
52.25 ± 9.29 
50.83 ± 9.77 






0.1mg 0.99 ± 0.12 
1.00 ± 0.09 
0.99 ± 0.10 
0.99 ± 0.10 
0.99 ± 0.14 
1.00 ± 0.17 
1.04 ± 0.16 
0.98 ± 0.11 
1.00 ± 0.11 
1.00 ± 0.12 
1.02 ± 0.10 





0.1mg 52.83 ± 8.28 
52.00 ± 9.72 
52.75 ± 9.12 
52.58 ± 8.56 
52.83 ± 8.28 
52.00 ± 9.72 
52.75 ± 9.12 
52.58 ± 8.56 
53.08 ± 8.55 
51.92 ± 9.69 
52.75 ± 9.08 
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Table 2. Results of the repeated measures ANOVA.  





Medication x Stimulation 
Medication x Time 
Stimulation x Time 
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Medication x Time 
Stimulation x Time 






















*Significant results at p < 0.05.  
 





Figure 1. Course of the study. In the beginning of each session, before administration of 
varenicline or placebo medication, 25 baseline single pulse MEPs were recorded at an intensity 
to elicit MEPs with peak-to-peak amplitudes of on average 1 mV. Three hours later, a second 
baseline was recorded to explore the effect of medication on cortical excitability, and adjusted, if 
necessary (third baseline). Afterwards, tDCS (cathodal or anodal) or PAS (PAS10 or PAS25) was 
administered and 25 MEPs were recorded immediately after stimulation and at time points of 5, 
10, 15, 20, 25, 30, 60, 90 and 120 minutes after plasticity induction. Further TMS measurements 
were conducted in the evening of the same day (SE), next morning, at ~9:00AM (NM), next noon, 
at ~12:00PM (NN) and next evening, at ~6:00PM (NE). 
 







Figure 2. Impact of varenicline on tDCS-induced neuroplasticity. Shown are baseline-normalized 
MEP amplitudes after plasticity induction by anodal (A) and cathodal (B) tDCS under 0.1mg, 
CHAPTER 2 – ORIGINAL ARTICLES AND MANUSCRIPTS 
 
59 
0.3mg, 1.0mg varenicline or placebo medication conditions up to the evening of the post-
stimulation day. A. In the placebo and 0.1mg varenicline medication conditions, anodal tDCS 
induced a significant excitability elevation up to 60 minutes after stimulation, which was 
abolished by 0.3mg and 1.0mg varenicline. B. In the placebo, 0.1mg and 1.0mg varenicline 
medication conditions, cortical excitability was significantly reduced after cathodal tDCS 
administration. This effect was abolished by 0.3mg varenicline. Error bars indicate S.E.M. Filled 
symbols indicate significant differences of post-stimulation MEP amplitudes from respective 
baseline values; asterisks indicate significant differences between the drug and placebo 
medication conditions at the same time points (Student’s t-test, two tailed, paired samples, p < 
0.05).  







Figure 3. Impact of varenicline on PAS-induced neuroplasticity. Shown are baseline-normalized 
MEP amplitudes after plasticity induction by PAS25 (A) and PAS10 (B) under 0.1mg, 0.3mg, 
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1.0mg varenicline or placebo medication conditions up to the evening of the post-stimulation 
day. A. Cortical excitability was significantly elevated up to 30 minutes in all medication 
conditions after PAS25 administration. B. In the placebo and 0.1mg varenicline medication 
conditions, cortical excitability was significantly reduced up to 60 minutes after PAS10. 0.3mg 
and 1.0 mg varenicline abolished the above mentioned excitability diminution. Error bars 
indicate S.E.M. Filled symbols indicate significant differences of post-stimulation MEP amplitudes 
from respective baseline values; asterisks indicate significant differences between the drug and 
placebo medication conditions at the same time points (Student’s t-test, two tailed, paired 






Figure 4. Both, anodal and cathodal tDCS-induced plasticity is abolished by 0.3mg varenicline, 
Anodal tDCS-induced excitatory plasticity is abolished and cathodal tDCS-induced inhibitory 
plasticity is preserved by 1.0mg varenicline. 0.1mg varenicline has no impact on stimulation-
induced plasticity. Medium and high doses of varenicline abolished PAS10-induced inhibitory 
plasticity. Varenicline at any doses did not have an impact on PAS25 induced excitability 
enhancement. Each column represents the mean of baseline-normalized MEP ± S.E.M. 
amplitudes until 30 minutes after stimulation; Asterisks indicate significant differences between 
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Chapter 3 – Summary and Conclusions 
 
The studies presented in this thesis explore different aspects of neuroplasticity in the human 
brain. The first study demonstrated a non-linear association between tDCS intensity and its after 
effects. An enhancement of tDCS intensity is not always accompanied by an increase of efficacy 
of stimulation, but might also shift the direction of excitability alterations as in case of 2mA 
cathodal stimulation. Similar non-linear associations between stimulation intensity and after-
effects have been previously shown for other non-invasive brain stimulation protocols (rTMS, 
tRNS, tACS) (Doeltgen and Ridding, 2010, Moliadze et al., 2012). This finding should especially be 
considered with regard to clinical application of the stimulation technique. These results also 
imply that before therapeutical administration of modified stimulation protocols, it is necessary 
to study their physiological effects. The results of this study also lead to the assumption that in 
healthy individuals a “ceiling effect” exists that cannot be surpassed by simply increasing the 
intensity and/or duration of the stimulation. For achieving desired longer and stronger 
stimulation after-effects, the use of repeated stimulation protocols and pharmacological 
interventions is suggested (Nitsche et al., 2004, Kuo et al., 2008, Nitsche et al., 2009, Monte-Silva 
et al., 2010a, Monte-Silva et al., 2013). These non-linear physiological effects are reflected by the 
results of cognitive studies, where the impact of different tDCS intensities is even less uniform. 
Some studies show performance improvement via 2mA tDCS compared to 1mA (Iyer et al., 2005, 
Moos et al., 2012), the opposite effect (Hoy et al., 2013) or no difference (Teo et al., 2011). 
Beyond non-linear effects of tDCS applied with different intensities on the affected neurons, and 
an interaction between stimulation- and cognition-dependent neuronal activation, which might 
differ from the effect of “tDCS-only” conditions, another reason for such non-linear effects might 
be that increased intensity of the transcranially injected electric current could lead to increased 
electric field strength in subcortical regions and additional recruitment of adjacent, non-target 
brain regions, resulting in altered plasticity and functional connectivity (Boros et al., 2008, Datta 
et al., 2009, Polania et al., 2011a, Polania et al., 2011b, Polania et al., 2012, Kessler et al., 2013). 
However, these hypotheses are speculative and should be subject of future experiments. 
In contrast to these results, several clinical studies (Boggio et al., 2006, Fregni et al., 2006a, 
Fregni et al., 2006b, Brunoni et al., 2011, Brunelin et al., 2012) demonstrate a positive impact of 
2mA stimulation. In neuropsychiatric diseases, pathologically altered brain plasticity, and 
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activity, and thus an altered pre-stimulation state of brain physiology, could be the reason for 
the effectiveness of stronger/longer tDCS protocols, broadening the range in which plasticity 
alterations aimed for can be accomplished. Previous studies showed clearly that the basal state 
of cortical activity, and excitability have a relevant impact on the kind of plasticity induced 
(Siebner et al., 2004, Fricke et al., 2011). Thus the results of our study, conducted in healthy 
young participants and using the primary motor cortex as a model, might not translate one-to-
one to patient populations or cognitive experiments.  
The second and third studies addressed the knowledge gaps with regard to the involvement of 
certain neuromodulatory systems and receptors in specific plasticity types. In principal 
accordance to previous studies (Normann et al., 2007, Nitsche et al., 2009), the results of the 
second study demonstrate an enhancement of LTP-like plasticity and a reduction of LTD-like 
plasticity by serotonin, therefore shifting resulting net plasticity into the direction of facilitation. 
This might explain the positive effect of serotonin enhancers on rehabilitation in diseases, such 
as stroke and depression, accompanied by enhanced inhibitory and reduced excitatory plasticity 
(Foy et al., 1987, Dam et al., 1996, Traversa et al., 1997, Xu et al., 1997, Traversa et al., 1998, 
Pariente et al., 2001, Schaechter, 2004, Chollet et al., 2011, Player et al., 2013). Given that PAS-
induced plasticity is related to STDP (Stefan et al., 2000, Wolters et al., 2003), these results are 
also helpful for explaining the positive serotoninergic impact on cognitive processes (Loubinoux 
et al., 1999, Loubinoux et al., 2002a, Loubinoux et al., 2002b, Loubinoux et al., 2005).  
It is hypothesized that 5-HT2 and 5-HT3 are candidate receptors in serotoninergic modulation of 
plasticity, as they modulate intracellular Ca2+ concentration (Reiser et al., 1989, Ronde and 
Nichols, 1998). However, their specific impact on plasticity is not yet clear and has to be studied 
in future experiments using respective agonist and antagonist pharmacological agents and 
different plasticity-inducing protocols. 
The third study sheds some light on the dose-dependency of  nicotinic receptor activation 
on neuroplasticity. So far, the involvement of specific receptors in nicotine-modulated human 
brain plasticity remained unclear. In this project, we used different doses of the  nicotinic 
receptor partial agonist varenicline (Mihalak et al., 2006) and studied their impact on 
stimulation-induced non-focal and focal plasticity of the human primary motor cortex. The 
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results of this study show that a low dose of varenicline has no impact on cortical plasticity, 
while a medium dose preserves only focal facilitatory plasticity, whereas it abolishes other 
plasticity types. Varenicline in high doses preserved focal facilitatory and non-focal inhibitory 
plasticity. The results obtained under the medium-dose are identical to those of global nicotinic 
activation (Thirugnanasambandam et al., 2012). In high doses, preservation of non-focal 
inhibitory plasticity by varenicline could be explained by its antagonist effect in high dosages and 
therefore reduced calcium influx. The results of this study are in accordance with a crucial 
importance of this receptor for the modulatory impact of nicotine on plasticity, which most 
probably is driven by intracellular calcium alterations. Besides ,  nAChRs also have Ca
2+ 
channel properties (Burnashev, 1998, Dajas-Bailador and Wonnacott, 2004), therefore it is 
essential to study their impact on neuroplasticity in order to fully explore the contribution of 
nicotinic receptors (Matsuyama and Matsumoto, 2003).  
With regard to the functional importance of this finding, it is relevant to notice that nicotine 
withdrawal impairs memory functions and neuroplasticity in smoking individuals and its 
readministration restitutes them (Cole et al., 2010, Grundey et al., 2012). Taking into account 
that varenicline is a popular smoking cessation drug (Coe et al., 2005) and has been shown to 
improve memory functions in nicotine abstinence (Patterson et al., 2009, Loughead et al., 2010), 
its possible restitutive effect on tobacco consumption-related impaired plasticity and cognitive 
functions might contribute to diminishing the probability to relapse in smoking addicts after 
cessation, which will be interesting to explore in future experiments.  
Possible limitations of the second and third studies is that we administered single oral doses of 
citalopram and varenicline. Many studies demonstrate that chronic exposure to 
neuromodulatory substances can lead to desensitization or up- and downregulation of receptors 
(Wonnacott, 1990, Blier and Bouchard, 1994, Pineyro et al., 1994, Hsu et al., 1996, Fenster et al., 
1997, Fenster et al., 1999, Buisson and Bertrand, 2001, Yamane et al., 2001), therefore the 
effects of these substances on neuroplasticity under chronic administration, as relevant for 
clinical application, could be qualitatively different from those after a single-dose. This important 
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